Wnt Signaling And Colorectal Cancer
What is this
This trend focuses on the complex role of Wnt/β-Catenin signaling in colorectal cancer, emphasizing the interplay with post-transcriptional RNA regulation and associated molecular pathways. It highlights emerging research that links cellular signaling with cancer progression and potential therapeutic targets.
Why it matters
As colorectal cancer remains one of the most common and lethal cancers globally, new insights into its molecular drivers are crucial. Advances in understanding Wnt signaling now offer prospects for targeted therapies, driven by an increasing volume of high-quality research and clinical evidence.
Investment angle
Investors might look at biotech and pharmaceutical companies that are prioritizing targeted therapeutic approaches in colorectal cancer. Specific opportunities include investing in startups developing Wnt pathway modulators or established firms expanding their precision oncology pipelines.
A promising investment play in precision oncology with targeted biotech opportunities; Investability: 7/10.
History
| date | signals | new | substance |
|---|---|---|---|
| 2026-03-10 | 17 | 100% | |
| 2026-03-22 | 60 | +43 | 100% |
| 2026-04-03 | 63 | +3 | 100% |
| 2026-04-15 | 67 | +4 | 100% |
| 2026-04-27 | 73 | +6 | 100% |
| 2026-05-09 | 74 | +1 | 100% |
| 2026-05-23 | 86 | +12 | 100% |
| 2026-06-03 | 89 | +3 | 100% |
| 2026-06-15 | 93 | +4 | 100% |
| 2026-06-27 | 94 | +1 | 100% |
| 2026-07-09 | 99 | +5 | 100% |
| 2026-07-20 | 103 | +4 | 100% |
| 2026-08-01 | 105 | +2 | 100% |
| 2026-08-13 | 110 | +5 | 100% |
Evidence
- 2026-08-12OpenAlexGALNT2-mediated O-GalNAcylation of METTL3 promotes radioresistance in esophageal squamous cell carcinoma by stabilizing GPX4 mRNA via m6A modification · detail
- 2026-08-10PubMedTargeting Spatiotemporal Heterogeneity of oncomiRNAs: A New Frontier in Cancer Therapy. · detail
- 2026-08-10PubMedFrom KRAS inhibition to tumor adaptation: mechanistic layers of resistance and therapeutic strategies. · detail
- 2026-08-04PubMedRewiring the tumor microenvironment: IGFBP2 at the Nexus of remodeling and therapy resistance? · detail
- 2026-08-03PubMed[Psoralen inhibits liver metastasis of colorectal cancer by regulating Notch/Snail pathway]. · detail
- 2026-07-30PubMedDevelopmentally constrained plasticity as a therapeutic vulnerability in cancer. · detail
- 2026-07-26NIH RePORTERBase editing to elucidate RAF regulation and signaling · detail
- 2026-07-18PubMedA ferroptosis-suppressive state drives resistance to bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer. · detail
- 2026-07-13PubMedTargeting long non-coding RNA H19 attenuates PKM2 deficiency-driven stemness property in tongue cancer. · detail
- 2026-07-12NIH RePORTERTumor-Niche Co-evolution: Mechanisms Driving Ovarian Cancer Metastasis and Therapeutic Resistance · detail
- 2026-07-12NIH RePORTERReprogramming Epithelial WIRing to Eradicate CANcer (REWIRE-CAN) · detail
- 2026-07-09PubMedMolecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making. · detail
- 2026-07-06NIH RePORTERImproving the translational value of head and neck cancer patient-in-mouse models · detail
- 2026-07-01OpenAlexFAM107A inhibits Invasion and migration of colorectal cancer by affecting EMT via the AKT pathway. · detail
- 2026-06-29PubMedKIF7 promotes the proliferation of clear cell renal cell carcinoma by activating the WNT/β-catenin signaling pathway. · detail
- 2026-06-28NIH RePORTERThe Role of the Y Chromosome in Bladder Tumor Development, Growth And Progression · detail
- 2026-06-22PubMedRole of WDR66 in Stemness, Therapy Resistance and Tumor microenvironment modulation in Head and Neck Cancer. · detail
- 2026-06-14NIH RePORTERFOSL1-super-enhancers define cisplatin-enriched cancer stem cells in HNSCC · detail
- 2026-06-07NIH RePORTERNaturally Occurring Canine Hemangiosarcoma as a Translational Model for Angiosarcoma · detail
- 2026-06-07PubMedMulti-dimensional profiling of lactylation-related signatures for prognostic and therapeutic insights in bladder cancer. · detail